TW201141510A - Pharmaceutical compositions for the stimulation of stem cells - Google Patents

Pharmaceutical compositions for the stimulation of stem cells Download PDF

Info

Publication number
TW201141510A
TW201141510A TW099141986A TW99141986A TW201141510A TW 201141510 A TW201141510 A TW 201141510A TW 099141986 A TW099141986 A TW 099141986A TW 99141986 A TW99141986 A TW 99141986A TW 201141510 A TW201141510 A TW 201141510A
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
group
fgf
pharmaceutical
page
Prior art date
Application number
TW099141986A
Other languages
English (en)
Chinese (zh)
Inventor
Roland Gordon-Beresford
Vinciane Gaussin
Christian Homsy
Dwan Isa Jean-Pierre Latere
Original Assignee
Cardio3 Biosciences Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardio3 Biosciences Sa filed Critical Cardio3 Biosciences Sa
Publication of TW201141510A publication Critical patent/TW201141510A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW099141986A 2009-12-02 2010-12-02 Pharmaceutical compositions for the stimulation of stem cells TW201141510A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2009066251 2009-12-02

Publications (1)

Publication Number Publication Date
TW201141510A true TW201141510A (en) 2011-12-01

Family

ID=42316097

Family Applications (1)

Application Number Title Priority Date Filing Date
TW099141986A TW201141510A (en) 2009-12-02 2010-12-02 Pharmaceutical compositions for the stimulation of stem cells

Country Status (12)

Country Link
JP (1) JP2013512877A (enExample)
KR (1) KR20120099751A (enExample)
CN (1) CN102711798A (enExample)
AU (1) AU2010326633A1 (enExample)
BR (1) BR112012013164A2 (enExample)
CA (1) CA2781493A1 (enExample)
IL (1) IL219901A0 (enExample)
MX (1) MX2012005976A (enExample)
NZ (1) NZ599930A (enExample)
RU (1) RU2012120834A (enExample)
TW (1) TW201141510A (enExample)
WO (1) WO2011067317A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160000699A1 (en) * 2014-07-07 2016-01-07 Medipost Co., Ltd. Hair growth promoting capacity of conditioned media of stimulated stem cells and use thereof
CN105079791A (zh) * 2015-09-18 2015-11-25 郑榆坤 一种刺激体内内源干细胞的组合物及其应用
RU2634576C1 (ru) * 2016-10-24 2017-10-31 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ стимуляции регенерации тканей
CN107050428B (zh) * 2017-03-23 2020-05-05 温州医科大学 Fgf20药物及其对脑创伤的治疗应用
CN107648592B (zh) * 2017-11-13 2021-05-14 深圳市喆邦生物工程有限公司 趋化因子ccl4作为制备治疗骨折药物的应用
RU2686718C1 (ru) * 2018-03-12 2019-04-30 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство, стимулирующее функции мезенхимальных клеток-предшественников in vitro
KR102106710B1 (ko) 2018-10-11 2020-05-04 강원대학교산학협력단 인간 전분화능 줄기세포로부터 조혈모세포 및 대식세포 분화 증진 방법
CN111195350A (zh) * 2020-01-15 2020-05-26 重庆大学 IGF1和IGF1Ec24联合在制备促进组织修复与再生的药物中的应用
WO2021187895A1 (ko) * 2020-03-17 2021-09-23 주식회사 히에라바이오 심장줄기세포를 포함하는 허혈성 질환의 예방 또는 치료용 조성물
CN111621525B (zh) * 2020-06-18 2021-04-23 中赛干细胞基因工程有限公司 Stx1b基因在促进人脂肪间充质干细胞生长和分化中的用途
KR20240131080A (ko) * 2023-02-23 2024-08-30 서울대학교산학협력단 배외내배엽 줄기세포의 배양용 배지 조성물
CN116836920B (zh) * 2023-08-21 2024-05-24 广东横琴粤澳深度合作区齐美国际干细胞医院有限公司 一种无血清培养基及其制备间充质干细胞的方法
KR102990665B1 (ko) * 2024-09-19 2026-07-15 부산대학교 산학협력단 Ccl5를 포함하는 골수 유래 줄기세포의 활성화 촉진용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173118B2 (en) * 2004-07-30 2012-05-08 Mayo Foundation For Medical Education And Research Compositions consisting essentially of TGF-β, BMP-2 FGF-4, leukemia inhibitory factor, IGF-1, IL-6 and H-α-thrombin
EP2236153A3 (en) * 2005-01-25 2012-08-22 Five Prime Therapeutics, Inc. Compositons and methods for treating cardiac conditions
US9765298B2 (en) * 2006-07-24 2017-09-19 Mayo Foundation For Medical Education And Research Methods and materials for providing cardiac cells
US8481075B2 (en) * 2007-12-13 2013-07-09 Beijing Shengyiyao Science & Technology Development Co. Ltd. Preparation and application of biodegradable-material-made microsphere vascular embolus containing liposome-encapsulated cytokines

Also Published As

Publication number Publication date
IL219901A0 (en) 2012-07-31
JP2013512877A (ja) 2013-04-18
RU2012120834A (ru) 2014-01-20
AU2010326633A1 (en) 2012-05-31
KR20120099751A (ko) 2012-09-11
MX2012005976A (es) 2012-06-25
BR112012013164A2 (pt) 2016-03-01
CA2781493A1 (en) 2011-06-09
WO2011067317A1 (en) 2011-06-09
NZ599930A (en) 2014-04-30
CN102711798A (zh) 2012-10-03

Similar Documents

Publication Publication Date Title
EP2506867B1 (en) Pharmaceutical compositions for the stimulation of stem cells.
WO2011067317A1 (en) Pharmaceutical compositions for the stimulation of stem cells.
Price et al. Intravenous mesenchymal stem cell therapy early after reperfused acute myocardial infarction improves left ventricular function and alters electrophysiologic properties
EP1465653B1 (fr) Application therapeutique du g-csf
Sanganalmath et al. Hematopoietic cytokines for cardiac repair: mobilization of bone marrow cells and beyond
Pourrajab et al. Application of stem cell/growth factor system, as a multimodal therapy approach in regenerative medicine to improve cell therapy yields
KR20240012562A (ko) 소규모 뇌졸중에 대한 세포 치료법 및 치료 방법
Li et al. Enhanced human adipose‐derived stem cells with VEGFA and bFGF mRNA promote stable vascular regeneration and improve cardiac function following myocardial infarction
US20060110374A1 (en) Method to accelerate stem cell recruitment and homing
US20080102059A1 (en) Treatment for arthritis
RU2248216C2 (ru) Композиция и способ увеличения количества стволовых клеток и/или гематопоэтических клеток-предшественников в циркуляции в периферической крови млекопитающих
WO2003061686A1 (fr) Application therapeutique des facteurs g-csf, gm-csf et scf
Zisa et al. Intramuscular VEGF activates an SDF1-dependent progenitor cell cascade and an SDF1-independent muscle paracrine cascade for cardiac repair
Jeon et al. Synergistic effect of sustained delivery of basic fibroblast growth factor and bone marrow mononuclear cell transplantation on angiogenesis in mouse ischemic limbs
Waksman et al. Bone marrow and bone marrow derived mononuclear stem cells therapy for the chronically ischemic myocardium
AU2001258322A1 (en) Formulation having mobilising activity
Louzada et al. Granulocyte-colony stimulating factor treatment of chronic myocardial infarction
Edelberg et al. Translation of PDGF cardioprotective pathways
Davis The cell engraftment hypothesis of cardiac repair
JP4775663B2 (ja) 血管新生制御方法
Hiesinger et al. Angiogenic Cytokine Therapy for Ischemic Heart Disease
Zelarayán et al. Emerging Concepts in Myocardial Pharmacoregeneration
McDaniel et al. Intramuscular VEGF activates an SDF1-dependent
Patel et al. Safety and efficacy of ixmyelocel-T, an expanded patient-specific mixed cell product, in dilated cardiomyopathy (IMPACT-DCM)
Beohar et al. Cytokine treatment for cardioprotection and cardiac regeneration